CVS Health® is committed to promoting the use of high-quality, cost-effective medications, including biosimilar drugs. These medications are essential for patients who require treatment for chronic and severe conditions. Biosimilars can be used to treat a wide range of conditions, from certain types of cancer to diabetes, and they represent a significant opportunity for managing drug costs within the healthcare system.
A recent report written by Dr. Sree Chaguturu, Executive Vice President and Chief Medical Officer at CVS Health, highlights the benefits of biosimilar drugs in making treatments more affordable. The report also discusses the role of Cordavis™, a CVS Health subsidiary that focuses on producing high-quality biosimilars, in improving patient access to these life-changing treatments and driving innovation in healthcare.
Cordavis™ produces biosimilars that are similar in safety and efficacy to branded drugs but at a lower cost. This makes them accessible to more patients who may not have been able to afford the branded version of the drug. The company’s focus on quality control and rigorous testing ensures that their products meet or exceed regulatory standards and are safe for use in patients.
In addition to improving patient access to medications, Cordavis™ is also driving innovation in healthcare by developing new biosimilar drugs that address unmet medical needs. By doing so, they are helping to make treatments more effective and efficient while reducing costs for patients and healthcare providers alike.
To learn more about the impact of biosimilar drugs and how they are making healthcare more accessible, you can read the full report (PDF) authored by Dr. Sree Chaguturu.